CardiaBeats European roll-out continues

By Alex McNally

- Last updated on GMT

Related tags: Atherosclerosis, Cholesterol

Enzymotec has taken another step in rolling out its CardiaBeat
heart health ingredient, signing an agreement with Genexo to see it
enter the Polish market.

The Israeli firm has already signed deals to see the ingredient launch in the India and Australian market, and has said it will expand further into Europe by the end of the year. The deal with Genexo signals continued growth for Enzymotec, which last month announced it will build a new 200,000 sq foot research and development centre to meet "growing demand." The ingredient is an extension of Enzymotec's functional oil formulation MultOil, which has been shown to potentially reduce the risk for coronary heart disease through preventing and controlling oxidative stress, reducing total cholesterol and triglyceride levels and inhibiting the atherosclerotic plaque formation cascade. The means it tackles more heart health indicators than many ingredients on the market, which look only after cholesterol management. CardiaBeat also enhances the impact of plant sterols and omega-3s on cardiovascular disease (CVD) risk reduction, the firm added. Marketing manager Michal Haim-Bravman said: "I am proud that Genexo have found CardiaBeat as a complementary dietary supplement to the current drug line they have for CVD. Signing of this agreement … is an important milestones in our sales and marketing strategy for CardiaBeat in Europe. We expect to finalize more strategic agreements before the end of this year." ​ According to several market reports published in the last three years, the demand for dietary supplements in Poland is growing due to increasing willingness to self-medicate and the awareness for CVD and its prevention, Enzymotec said. Indeed, a survey in April by Poland-based market research company PMR said a rise in sales of dietary supplements was brought on by society's wish to live a healthier life. Genexo is a private Polish pharmaceutical company offering products for the diagnosis, treatment and prevention of metabolic diseases including diabetes, hypercholesterolemia, and obesity. In August Enzymotec said a new R&D centre, due to be completed by the end of the year, will help the company to meet increasing demand for its products. Enzymotec said yesterday that the building was needed to answer a rise in demand for its product, particularly GPC and Krill Oil, which could not be handled by its current facilities. The hub will also be used to produce its "brain energizer" ingredient Sharp PS which is a form of phosphatidylserine, and CardiaBeat.

Related news

Show more

Related products

show more

Does my Nutraceutical Need a Clinical Trial?

Does my Nutraceutical Need a Clinical Trial?

dicentra – CRO and regulatory consulting firm | 03-Aug-2020 | Technical / White Paper

The global nutraceutical industry is growing at an unprecedented rate. However, companies preparing to bring new and innovative products to the burgeoning...

Supporting cardiovascular health with probiotics

Supporting cardiovascular health with probiotics

Deerland Probiotics & Enzymes | 03-Aug-2020 | Technical / White Paper

Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of cardiovascular disease. Evidence exists...

Related suppliers

Follow us

Products

View more

Webinars